CymaBay Therapeutics, Inc. CBAY
Set alert
At close · Mar 21
52-week range unavailable
- Open
- 32.49
- Prev close
- 32.48
- Mkt cap
- 3.73B
- Vol
- 8.35M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 32.48
- High
- 32.50
- Forward P/E
- -30.93
- Beta
- 0.32
- Short ratio
- 0.84
- Inst. own
- 103.13%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 28, 2024
- 50-d avg
- 29.11
- 200-d avg
- 19.07
- 1y target
- 32.50
News
4 months ago gurufocus.com
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutical company focused on developing novel therapies for debili
2 years ago businesswire.com
Gilead Sciences Announces Completion of Acquisition of CymaBay
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY)…
2 years ago globenewswire.com
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA
2 years ago zacks.com
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.
2 years ago globenewswire.com
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
2 years ago prnewswire.com
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
- Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo - NEWARK, Calif.
2 years ago globenewswire.com
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic…
2 years ago businesswire.com
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CymaBay…
2 years ago investopedia.com
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3…
-
2 years ago benzinga.com
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P…
2 years ago prnewswire.com
Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead
MILWAUKEE , Feb. 12, 2024 /PRNewswire/ -- Ademi LLP is investigating CymaBay (Nasdaq: CBAY) for possible breaches of fiduciary duty and other violations of law in its transaction with Gilead. Click…
2 years ago investorplace.com
Why is CymaBay (CBAY) Stock Up 25% Today?
CymaBay (NASDAQ: CBAY ) stock is rising higher on Monday after the clinical-stage biopharmaceutical company announced an acquisition agreement with Gilead Sciences (NASDAQ: GILD ). That deal has…
2 years ago businesswire.com
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) to Gilead Sciences, Inc. for $32.50 per share…
2 years ago invezz.com
Gilead to buy CymaBay Therapeutics for $4.3 billion
CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of…
2 years ago prnewswire.com
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
- FDA has granted Priority Review with a target PDUFA date of August 14 - NEWARK, Calif. , Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused…
2 years ago reuters.com
Drugmaker Gilead to acquire CymaBay for $4.3 bln
Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.
2 years ago marketwatch.com
Gilead strikes deal to acquire CymaBay for $4.3 billion
Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday,…
2 years ago businesswire.com
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead…
2 years ago globenewswire.com
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic…
2 years ago globenewswire.com
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic…
2 years ago prnewswire.com
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
-- First clinical trial in PBC to show coordinate reductions of IL-31, bile acids and pruritus -- NEWARK, Calif. , Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a…
-
2 years ago benzinga.com
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023
-
3 years ago benzinga.com
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
-
3 years ago benzinga.com
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top…
-
3 years ago benzinga.com
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
-
3 years ago benzinga.com
Earnings Scheduled For May 15, 2023
Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is projected to report earnings for its first quarter.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
-
3 years ago benzinga.com
Earnings Scheduled For March 16, 2023
Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million.
-
3 years ago benzinga.com
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
-
4 years ago benzinga.com
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
-
4 years ago benzinga.com
79 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying…
-
4 years ago benzinga.com
Earnings Scheduled For May 12, 2022
Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 1043 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 351 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 849 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 721 companies achieved new lows for the year.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 431 companies hit new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 136 companies reached new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 282 companies set new 52-week lows.
-
5 years ago benzinga.com
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
-
5 years ago benzinga.com
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
-
5 years ago benzinga.com
Earnings Scheduled For November 5, 2020
Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX:BRG) is expected to report quarterly loss at $0.64 per share on revenue of $52.59 million.